PFD Management Shares NKC End-Of-Year Development Report
PFD is proud to share this end-of-year update on Neuro-Kinesis Corporation which is one of the featured medical technology companies in the PFDMOF3001 Opportunity Fund portfolio.
PFD Management Opportunity Fund 3001 Press Release November 15, 2022
PFD is proud to share Neuro-Kinesis Corporation’s fourth quarter 2023 update on it Huygens™ Catheter and Proteus™ Robotic Arm Technologies. this end-of-year update on Neuro-Kinesis Corporation is one of the featured medical technology companies in the PFDMOF3001 Opportunity Fund portfolio.
NKC Release Third Quarter Development Report on the Huygens – Proteus™ Robotic Arm Surgical Platform
Neuro-Kinesis Corporation has released its Third-Quarter Development Report on its Huygens™ Catheter and Proteus™ Robotic Arm Technologies. which is one of the featured medical technology companies in the PFDMOF3001 Opportunity Fund portfolio. The report includes information on the company’s application for Institutional Animal Care and Use Committee Approval (IACUC) for its upcoming animal studies as well as its agreement with Abbott/St. Jude for use of its EnSite NavX System in the NKC Operating Suite.
NKC Announces Upcoming Animal Study for Clinical Validation of its Huygens™ – Proteus™ Robotic Arm Surgical Platform
PFD shares this press release from Neuro-Kinesis Corporation, one of the medical technology comanies in its PFDMOF3001 Opportunity Fund portfolio which discusses the NKC’s announcement of two upcoming studies to be performed at the Technion Institute in Israel and at Sandia National Laboratories. Each of these studies are being done to validate the technology behind its Huygens™ Catheter platform.
Phase One Development of Huygens™ Smart Catheter & Proteus™ Robotic Platform Completed
PFD is pleased to share this press release from Neuro-KInesis, Corp. (NKC), one of the medical technology companies in the PFDMOF3001 Opportunity Fund. In the release NKC announced they have completed the Phase One development for their new Huygens™ Smart Catheter and Proteus™ Robotic Arm platform as well as five other strategic goals towards its efforts to bring its patented EP Catheter Mapping and Guidance Technology to the Electrophysiology marketplace.